# US 2008/0075739 A1 · Attenuated Salmonella SP12 Mutants as Antigen Carriers

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0075739 A1
- Document ID: US20080075739A1
- Status: Published application
- Kind: A1
- Application number: 11/840,928
- Filed: 2007-08-17
- Published: 2008-03-27
- Earliest claimed: 1998-09-04
- Assignees: Microscience Limited; Imperial College Innovations Limited
- Inventors: Michael Hensel; David Holden; Jacqueline Shea
- Web page: https://patentgrep.com/patent/US20080075739A1

## CPC

- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 31/04: Antibacterial agents
- A61P 31/12: Antivirals
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07K 14/255: Salmonella (G)
- C12N 1/36: Adaptation or attenuation of cells
- C12N 15/87: Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 2035/11: {Medicinal preparations comprising living procariotic cells}
- A61K 2039/522: {avirulent or attenuated}
- A61K 2039/523: {expressing foreign proteins}
- C07K 2319/00: Fusion polypeptide
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention relates to vaccines, in particular, to an attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell, and to a carrier for the presentation of an antigen to a host, which carrier is said attenuated gram-negative cell, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.

## Claims

### Claim 1

An isolated nucleic acid molecule, comprising a nucleic acid sequence comprising at least 50 nucleotides
a) of the nucleic acid sequence of one of FIGS. 21A, B,
b) of an allele of the nucleic acid sequence of one of FIGS. 21A, B, or
c) of a nucleic acid sequence which under stringent conditions hybridizes with the nucleic acid sequence of one of FIGS. 21A, B.

### Claim 2 (depends on 1)

The nucleic acid molecule according to claim 1, wherein said nucleic acid sequence comprises at least 50 nucleotides
a) of the nucleic acid sequence of one of FIGS. 22A-Q.
b) of a nucleic acid sequence, which corresponds to the nucleic acid sequence of one of FIGS. 22A-Q within the degeneration of the genetic code, or
c) of a nucleic acid sequence which under stringent conditions hybridizes with the nucleic acid sequence of one of FIGS. 22A-Q.

### Claim 3 (depends on 2)

The nucleic acid molecule according to claim 2, wherein said nucleic acid sequence comprises
a) the nucleic acid sequence of one of FIGS. 22A-Q.
b) a nucleic acid sequence, which corresponds to the nucleic acid sequence of one of FIGS. 22A-Q within the degeneration of the genetic code, or
c) of a nucleic acid sequence which under stringent conditions hybridizes with the nucleic acid sequence of one of FIGS. 22A-Q.

### Claim 4 (depends on 1)

The nucleic acid molecule according to claim 1, wherein at least one coding region is functionally deleted.

### Claim 5 (depends on 1)

The nucleic acid molecule according to claim 1 having inserted therein at least one insertion cassette for transposon or phage mediated insertion.

### Claim 6 (depends on 1)

The nucleic acid molecule according to claim 1, wherein at least one heterologous nucleic acid molecule coding for a polypeptide or peptide is inserted or deletion-inserted.

### Claim 7 (depends on 6)

The nucleic acid molecule according to claim 6, wherein the sequences flanking said heterologous nucleic acid molecule each have a length of at least 50 nucleotides, preferred 200-250 nucleotides.

### Claim 8 (depends on 6)

The nucleic acid molecule according to claim 6, wherein said heterologous nucleic acid molecule comprises a nucleic acid sequence coding for a bacterial or viral antigen or homologue thereof.

### Claim 9 (depends on 6)

The nucleic acid molecule according to claim 6, wherein said heterologous nucleic acid molecule comprises a nucleic acid sequence coding for a tumor antigen.

### Claim 10 (depends on 7)

The nucleic acid molecule according to claim 7, wherein said heterologous nucleic acid molecule comprises at least one gene expression cassette.

### Claim 11 (depends on 7)

The nucleic acid molecule according to claim 7, wherein said heterologous nucleic acid molecule comprises at least one transactivator cassette, selective marker cassette, invertase cassette or combination thereof.

### Claim 12 (depends on 7)

The nucleic acid molecule according to claim 7, wherein said heterologous nucleic acid molecule comprises at least one nucleic acid sequence coding for a polypeptide or peptide targeting and/or immunostimulatory domain.

### Claim 13 (depends on 7)

A recombinant vector comprising the nucleic acid molecule according to claim 7.

### Claim 14 (depends on 5, 13)

A cell comprising the nucleic acid molecule according to claim 5 or the recombinant vector according to claim 13.

### Claim 15 (depends on 14)

The cell according to claim 14, wherein the cell is a gram-negative cell.

### Claim 16 (depends on 14)

The cell according to claim 14, wherein the cell is a Salmonella cell.

### Claim 17

A peptide or polypeptide comprising a peptide sequence comprising at least 20 amino acids
a) of the sequence of FIGS. 23A-Q, or
b) of a sequence which is 60% homologous to the sequence of FIGS. 23A-Q.

### Claim 18

A polypeptide comprising the sequence
a) of FIGS. 23A-Q, or
b) which is 60% homologous to the sequence of FIGS. 23A-Q.

### Claim 19 (depends on 17)

An antibody directed against the polypeptide according to claim 17.

### Claim 20 (depends on 17)

A fusion protein comprising the polypeptide according to claim 17 having inserted or deletion-inserted or being fused C- or NH2-terminally with at least one heterologous polypeptide.

### Claim 21 (depends on 20)

The fusion protein according to claim 20, wherein the heterologous polypeptide is selected from bacterial, viral or tumor antigens.

### Claim 22

An attenuated gram-negative cell comprising the SPI2 gene locus, wherein at least one gene of the SPI2 locus is inactivated, wherein said inactivation results in an attenuation/reduction of virulence compared to the wild type of said cell.

### Claim 23 (depends on 22)

The attenuated gram-negative cell according to claim 22, wherein at least one inactivated gene is selected from effector (sse) genes, secretion apparatus (ssa) genes, chaperon (ssc) genes and regulation (ssr) genes.

### Claim 24 (depends on 22)

The attenuated gram-negative cell according to claim 22, wherein said cell is an Enterobactericae cell, in particular, a Salmonella cell, a Shigella cell or a Vibrio cell.

### Claim 25 (depends on 24)

The attenuated gram-negative cell according to claim 24, wherein said cell is a Salmonella cell.

### Claim 26 (depends on 24)

The attenuated gram-negative cell according to claim 24, wherein said cell has a broad host range.

### Claim 27 (depends on 26)

The attenuated gram-negative cell according to claim 26, wherein said cell is a Salmonella serotype Typhimurium Definitive Type 104 (DT104) cell.

### Claim 28 (depends on 22)

The cell according to claim 22 wherein at least one inactivated gene is selected from sse, ssc and ssr.

### Claim 29 (depends on 22)

The cell according to claim 22, wherein at least one inactivated gene comprises at least one sse gene.

### Claim 30 (depends on 29)

The cell according to claim 29, wherein at least one sse gene is selected from sseC, sseD and sseE.

### Claim 31 (depends on 22)

The cell according to claim 22, wherein at least one inactivated gene comprises at least one ssr gene.

### Claim 32 (depends on 31)

The cell according to claim 31, wherein said at least one ssr gene is ssrB.

### Claim 33 (depends on 22)

The cell according to claim 22, wherein at least one inactivated gene comprises at least one ssc gene.

### Claim 34 (depends on 33)

The cell according to claim 33, wherein said at least one ssc gene is sscB.

### Claim 35 (depends on 22)

The cell according to claim 22, wherein at least one gene is inactivated by a mutation comprising a deletion.

### Claim 36 (depends on 35)

The cell according to claim 35, wherein said deletion comprises at least 6 nucleotides.

### Claim 37 (depends on 35)

The cell according to claim 35, wherein the mutation comprises a deletion of the complete coding sequence for said gene.

### Claim 38 (depends on 22)

The cell according to claim 22, wherein at least one gene is inactivated by a mutation comprising the insertion of a heterologous nucleic acid molecule.

### Claim 39 (depends on 35)

The cell according to claim 35, wherein said mutation is a non-polar mutation.

### Claim 40 (depends on 22)

The cell according to claim 22, wherein at least one additional gene located outside of the SPI2 locus is inactivated, wherein the inactivation results in a further attenuation/reduction of virulence compared to the wild type.

### Claim 41 (depends on 40)

The cell according to claim 40, wherein said additional gene comprises an aro gene.

### Claim 42 (depends on 41)

The cell according to claim 41, wherein said aro gene is aro A.

### Claim 43 (depends on 40)

The cell according to claim 40, wherein said additional gene is superoxide dismutase.

### Claim 44 (depends on 22)

The cell according to claim 22, comprising at least one selective marker cassette.

### Claim 45 (depends on 44)

The cell according to claim 44, wherein said selective marker cassette is capable of conferring an antibiotic resistance to the cell.

### Claim 46 (depends on 22)

The cell according to claim 22 comprising at least one gene expression cassette.

### Claim 47 (depends on 22)

The cell according to claim 22 comprising at least one transactivator cassette.

### Claim 48 (depends on 22)

The cell according to claim 22 comprising at least one invertase cassette.

### Claim 49 (depends on 22)

The cell according to claim 22 comprising at least one insertion cassette.

### Claim 50 (depends on 22)

A carrier for the presentation of an antigen to a host, which carrier is an attenuated gram-negative cell according to claim 22, wherein said cell comprises at least one heterologous nucleic acid molecule comprising a nucleic acid sequence coding for said antigen, wherein said cell is capable of expressing said nucleic acid molecule or capable of causing the expression of said nucleic acid molecule in a target cell.

### Claim 51 (depends on 50)

The carrier according to claim 50, wherein said nucleic acid molecule comprises a nucleic acid sequence coding for a bacterial or viral antigen or a tumor antigen.

### Claim 52 (depends on 51)

The carrier according to claim 51, wherein said nucleic acid sequence codes for an antigen from Helicobacter pylori, Chlamydia pneumoniae, Borrelia burgdorferi, Nanobacteria, Hepatitis virus, human papilloma virus or Herpes virus.

### Claim 53 (depends on 50)

The carrier according to claim 50, wherein said nucleic acid molecule is inserted into the SPI2 locus.

### Claim 54 (depends on 53)

The carrier according to claim 53, wherein said nucleic acid molecule is inserted into an sse gene.

### Claim 55 (depends on 54)

The carrier according to claim 54, wherein said sse gene is selected from sseC, sseD and sseE.

### Claim 56 (depends on 50)

The carrier according to claim 50, wherein said insertion is a non-polar insertion.

### Claim 57 (depends on 50)

The carrier according to claim 50, wherein the expression of said heterologous nucleic acid molecule is tissue specific.

### Claim 58 (depends on 50)

The carrier according to claim 50, wherein the expression of said heterologous nucleic acid is inducible.

### Claim 59 (depends on 50)

The carrier according to claim 50, wherein the expression of said heterologous nucleic acid is activated in a target cell.

### Claim 60 (depends on 59)

The carrier according to claim 59, wherein said target cell is a macrophage.

### Claim 61 (depends on 50)

The carrier according to claim 50, wherein said nucleic acid molecule comprises a nucleic acid sequence coding for a least one polypeptide or peptide targeting and/or immunostimulatory domain.

### Claim 62 (depends on 50)

The carrier according to claim 50, wherein said nucleic acid molecule codes for a fusion protein.

### Claim 63 (depends on 50)

The cell according to claim 50, wherein the expression product of said nucleic acid molecule remains in the cytosole of said carrier.

### Claim 64 (depends on 50)

The carrier according to claim 50, wherein the expression product of said nucleic acid molecule is directed to the periplasmatic space of said carrier.

### Claim 65 (depends on 50)

The carrier according to claim 50, wherein the expression product of said nucleic acid molecule is directed to the outer membrane of said carrier.

### Claim 66 (depends on 50)

The carrier according to claim 50, wherein the expression product of said nucleic acid molecule is secreted.

### Claim 67 (depends on 66)

The carrier according to claim 66, wherein the expression product of said nucleic acid molecule is secreted by the type III secretion system.

### Claim 68 (depends on 67)

The carrier according to claim 67, wherein the expression product of said nucleic acid molecule is secreted by the SPI2 type III secretion system.

### Claim 69

An attenuated gram-negative cell comprising the SPI2 gene locus, characterized by a lack of at least one SPI2 polypeptide, wherein said lack results in an attenuation/reduction of virulence compared to the wild type of said cell.

### Claim 70 (depends on 69)

The attenuated gram-negative cell according to claim 69, wherein said missing polypeptide is selected from effector (sse) polypeptides, secretion apparatus (ssa) polypeptides, chaperon (ssc) polypeptides 68 and regulatory (ssr) polypeptides.

### Claim 71 (depends on 69)

A carrier for the presentation of an antigen to a host, which carrier is an attenuated gram-negative cell according to claim 69, further characterized by the presence of at least one heterologous peptide or polypeptide having immunogenic properties.

### Claim 72 (depends on 22, 50)

A pharmaceutical composition, comprising as an active agent an immunologically protective living vaccine, which is an attenuated cell according to claim 22 or a carrier according to claim 50.

### Claim 73 (depends on 72)

The composition according to claim 72 together with pharmaceutically acceptable diluents, carriers and/or adjuvants.

### Claim 74 (depends on 72)

The composition according to claim 72, which is suitable for administration to a mucosal surface or via the parenteral route.

### Claim 75 (depends on 22)

A method for the preparation of a living vaccine, comprising providing a living gram-negative cell comprising the SPI2 locus and inactivating at least one gene of the SPI2 locus to obtain an attenuated gram-negative cell according to claim 22.

### Claim 76 (depends on 50, 75)

The method of claim 75, further comprising inserting at least one heterologous nucleic acid molecule coding for an antigen to obtain a carrier according to claim 50.

### Claim 77 (depends on 22, 50)

A method for the preparation of a living vaccine composition comprising formulating an attenuated cell according to claim 22 or a carrier according to claim 50 in a pharmaceutically effective amount together with pharmaceutically acceptable diluents, carriers and/or adjuvants.

### Claim 78 (depends on 22, 50)

A method for the detection of an attenuated cell according to claim 22 or a carrier according to claim 50, comprising providing a sample containing said cell and detecting a specific property not present in wild type.

### Claim 79 (depends on 22)

A method for establishing a library of attenuated gram-negative cells comprising obtaining at least two attenuated gram-negative cells according to a claim 22, determining the pathogenicities of said cells, and determining the relation of the pathogenicities of said cells.

### Claim 80 (depends on 79)

The method according to claim 79 further comprising determining the immunogenicities of said cells and determining the relation of the immunogenicities of said cells.

### Claim 81 (depends on 80)

The method of claim 80, wherein the determination of the immunogenicity is a determination of the humoral, cellular and/or mucosal immunogenicity.

### Claim 82 (depends on 50)

A method for establishing a library of attenuated carriers for the presentation of an antigen to a host, comprising obtaining at least two carriers according to claim 50 determining (a) the pathogenicities of said cells and the relation of the pathogenicities of said cells, and (b) determining the effect of said antigen presentation in said host and determining the relation of said effects caused by said cells.

### Claim 83 (depends on 82)

The method of claim 82, wherein the effect of antigen presentation is determined at humoral, cellular and/or mucosal level.

### Claim 84 (depends on 82)

The method according to claim 82 further comprising determining the immunogenicities of said cells and determining the relation of the immunogenicities of said cells, wherein said determination optionally is a determination of the humoral, cellular and/or mucosal immunogenicity.

### Claim 85 (depends on 22, 50)

The use of an attenuated cell according to claim 22 or a carrier according to claim 50 for the preparation of a drug for the preventive or therapeutic treatment of an acute or chronic disease caused essentially by a bacterium or virus.

### Claim 86 (depends on 85)

The use according to claim 85, wherein said disease is caused essentially by a Salmonella cell.

### Claim 87 (depends on 50)

The use of a carrier according to claim 50 for the preparation of a drug for the preventive or therapeutic treatment of a tumour.

### Claim 88 (depends on 1, 13)

The use of a nucleic acid molecule according to claim 1 or a vector according to claim 13 for the preparation of an attenuated cell, a living vaccine or a carrier for the presentation of an antigen to a host.

### Claim 89

(canceled)

### Claim 90

(canceled)

### Claim 91

An isolated nucleic acid molecule comprising a nucleic acid of at least 100 nucleotides
a) of the nucleic acid sequence of one of FIGS. 24A, B
b) of a nucleic acid sequence which under stringent conditions hybridizes with the nucleic acid sequence of one of FIGS. 24A, B.

### Claim 92 (depends on 91)

The nucleic acid molecule according to claim 91, wherein said nucleic acid molecule is capable of inducing the expression of a nucleic acid sequence coding for a peptide or polypeptide operatively linked to said nucleic acid molecule.

### Claim 93 (depends on 92)

Expression system for the in vivo inducible expression of a heterologous nucleic acid in a target cell, comprising a carrier cell for said heterologous nucleic acid, wherein said carrier cell comprises (a) a polypeptide having the amino acid sequence shown in FIG. 23P (ssrA) or a functional homologue thereof, (b) a polypeptide having the amino acid sequence shown in FIG. 23Q (ssrB) or a functional homologue thereof, and (c) the nucleic acid molecule according to claim 92.

### Claim 94 (depends on 91)

Expression system according to claim 91, wherein said target cell is a macrophage.

### Claim 95 (depends on 93)

Expression system according to claim 93, wherein said carrier cell is a Salmonella cell.

### Claim 96 (depends on 93)

The expression system according to claim 93, wherein said target cell comprises a gene expression cassette.

### Claim 97 (depends on 93)

The expression system according to claim 93, wherein said target cell comprises an insertion cassette.

### Claim 98 (depends on 93)

The expression system according to claim 93, wherein said target cell comprises a heterologous nucleic acid molecule coding for a peptide or polypeptide.

### Claim 99

(canceled)

### Claim 100

(canceled)
